MPLT (MapLight Therapeutics) Q4/FY2025 Earnings & Corporate Update

Market Cap: ~$823M Stage: Clinical (Phase 2) Focus: CNS / neuropsychiatry, muscarinic agonism

The Numbers

• Net Loss FY2025: $161.2M (up from $77.6M FY2024)

• R&D Expenses: $138.3M (up from $68.5M). Doubled year over year, driven by clinical trial costs, CMC, and stock-based comp from IPO RSU vesting

• G&A Expenses: $30.7M (up from $14.4M). Same IPO comp dynamic

• Cash Position: $453.1M as of 12/31/25

• Runway: Through 2027 per management guidance

Burn rate is running about $160M/year. With $453M in cash, that math gets them comfortably into 2027 with room to spare. This is one of the best-capitalized clinical-stage CNS companies in the space. No near-term dilution risk. A lot of the cost increase is non-cash stock comp from the October 2025 IPO, so real cash burn is lower than headline.

Pipeline

Lead program is ML-007C-MA, a muscarinic M1/M4 agonist. This is the next-gen play on the Karuna/BMS thesis. BMS paid $14B for KarXT (now Cobenfy). MapLight claims a cleaner molecule with potentially better side effect profile.

• ZEPHYR Phase 2 (Schizophrenia): ~300 patients, target enrollment in April 2026, topline results Q3 2026. Primary endpoint is PANSS total score change at Week 5. Two dose arms (210/3 mg BID, 330/6 mg QD) vs placebo. This is the big binary event

• VISTA Phase 2 (Alzheimer's Disease Psychosis): ~300 patients, topline results H2 2027. FDA Fast Track granted December 2025. Zero approved treatments for ADP. Greenfield opportunity

• IRIS Phase 2 (ML-004, Autism Spectrum Disorder): ~160 patients, enrollment complete, topline results Q3 2026. Different molecule (5-HT1B/1D agonist), targeting core social communication deficits. Almost nothing works in ASD

Pipeline depth play is ML-055, next-gen M1/M4 muscarinic agonist. Preclinical data shows significantly greater potency vs ML-007, potential for once-daily dosing and long-acting injectable. Candidate nomination expected 2026.

The Setup

Two Phase 2 readouts in Q3 2026 across two different mechanisms and two different indications. That's a lot of shots on goal in a single quarter. The muscarinic thesis is already validated by Cobenfy's approval. If ZEPHYR hits, you're looking at the next-gen successor to a $14B acquisition. If IRIS hits in ASD, that's a completely differentiated data asset with essentially no competition.

$453M in cash means no leverage for anyone trying to acquire this on the cheap. MapLight can negotiate from strength. But that same cash pile also means they can go it alone if the data supports it.

IPO'd October 2025, so this is still a young public company. Management executing well, both trials enrolling on or ahead of schedule.

Catalysts Ahead

• ZEPHYR target enrollment hit (April 2026)

• ZEPHYR Phase 2 topline results (Q3 2026)

• IRIS Phase 2 topline results (Q3 2026)

• ML-055 candidate nomination (2026)

• VISTA topline results (H2 2027)

M&A Score: 78/100. $823M cap is within takeout range for large pharma. Two Phase 2 readouts within 6 months. Massive unmet need across all three indications. Cash runway into 2027, no desperation. FDA Fast Track on ADP. Space validated by the $14B Karuna deal. The muscarinic vertical has active pharma interest. Minor deduction for the higher cap, they're not a micro-cap bargain buy.

Growth Score: 65/100. Pre-revenue but deep pipeline across three indications plus a next-gen program. $453M cash is best-in-class for clinical-stage CNS. Both trials executing ahead of schedule. No commercial infrastructure yet, no revenue path for years. But the platform depth and execution quality are above average for this stage.

Tag: Dual Catalyst. Both scores elevated. Q3 2026 is the inflection point. If either readout hits, this reprices significantly on standalone trajectory or acquisition premium. The muscarinic thesis is de-risked by Cobenfy, and MapLight is the clearest next-gen play.